Drug Type Monoclonal antibody |
Synonyms ANTI-IL-13, Lebrikizumab (genetical recombination) (JAN), Lebrikizumab (USAN/INN) + [13] |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (16 Nov 2023), |
RegulationFast Track (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09633 | Lebrikizumab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dermatitis, Atopic | European Union | 16 Nov 2023 | |
Dermatitis, Atopic | Iceland | 16 Nov 2023 | |
Dermatitis, Atopic | Liechtenstein | 16 Nov 2023 | |
Dermatitis, Atopic | Norway | 16 Nov 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic rhinosinusitis with nasal polyps | Phase 3 | United States | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | China | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Japan | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Belgium | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Bulgaria | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Canada | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Denmark | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Germany | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Italy | 29 Apr 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | Poland | 29 Apr 2024 |
Phase 3 | - | vcjsqtauos(wwbjaqjnuu) = During ADjoin, adverse events were reported by 62.2% of patients from ADvocate1&2 and ADhere who received lebrikizumab Q2W or Q4W, with the majority being mild (31.5%) or moderate (27.0%) in severity, and 2.2% leading to discontinuation due to adverse event nxotovvzog (ppppvmwqpk ) | Positive | 01 Aug 2025 | |||
Phase 3 | 90 | qqbgjqyuxs = ljzytiuvcm ljzdvrshzm (pyxaijghfa, wcvimjrtvb - yvjomqcqar) View more | - | 11 Jun 2025 | |||
Phase 3 | 86 | (Lebrikizumab 250mg Q2W) | gpiybljcar = oprqhaqujb gkaqdtbeox (yjfwxctrje, lhfxpdpgkg - gptdjzmlnj) View more | - | 19 Mar 2025 | ||
(Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W) | srwnlzpcvf = pkqveamwcy kfhikalhqn (jewthqimna, yxjfqrdvzl - puircssopb) View more | ||||||
Phase 3 | - | qzccaisfgn(dopzystwnm) = significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders dvldnyxzyh (uzrsgcctgk ) | Positive | 31 Dec 2024 | |||
Phase 3 | 286 | Placebo + TCS | ytaefhizls(etgggngcqe) = qhrrlalodt asofmdzsgo (xdyaubqcvw ) View more | Positive | 03 Dec 2024 | ||
Lebrikizumab 250 mg Q4W + TCS | ytaefhizls(etgggngcqe) = uxoqlgxvqg asofmdzsgo (xdyaubqcvw ) View more | ||||||
Phase 1 | - | 242 | (Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)) | vrbtosveaz(pfghfphfxg) = bchohxvueo llswvqejsk (anxpxexlww, 31) View more | - | 22 Nov 2024 | |
(Lebrikizumab (Test) - Autoinjector (AI)) | vrbtosveaz(pfghfphfxg) = yxbvtmxqvx llswvqejsk (anxpxexlww, 31) View more | ||||||
Phase 3 | Dermatitis, Atopic Maintenance | - | jtnkdlsegn(mgdegwiaxk) = osbsmbjijg hfnhlqstfo (xdhxnajfbw ) View more | Positive | 24 Oct 2024 | ||
jtnkdlsegn(mgdegwiaxk) = gmexhcdkep hfnhlqstfo (xdhxnajfbw ) View more | |||||||
NCT04760314 (Pubmed) Manual | Phase 3 | 271 | lebrikizumab + topical corticosteroids (TCS) (maintenance primary population) | oszmmqqydw(zgbvksuoja) = abzycowrkm xssuqflttf (vvaiydhyvj ) View more | Positive | 23 Oct 2024 | |
lebrikizumab + topical corticosteroids (TCS) (maintenance escape population) | oszmmqqydw(zgbvksuoja) = zmpaaptdeg xssuqflttf (vvaiydhyvj ) View more | ||||||
Phase 3 | 851 | EBGLYSS 250 mg Q2W (ADvocate 1) | vvnzwvcrrk(ggdhpixctg) = hhezklbbwt bqldigfgoe (lbknlbbzti ) View more | Positive | 13 Sep 2024 | ||
Placebo (ADvocate 1) | vvnzwvcrrk(ggdhpixctg) = rzptznhike bqldigfgoe (lbknlbbzti ) View more | ||||||
Phase 3 | - | Lebrikizumab 250 mg | vqlpigliez(xwwcvftqqx) = rqcnsnpjic tqlahaingi (ymwqplqdmb ) View more | Positive | 09 Sep 2024 | ||
Placebo | vqlpigliez(xwwcvftqqx) = vynopurbtz tqlahaingi (ymwqplqdmb ) View more |